Nizar J Bahlis (Nizar Bahlis)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 49

Top Topics

Acute Lymphoblastic Leukemia

Multiple Myeloma

Artificial Intelligence

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Blood cancer journal

Nature medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Herve Avet-Loiseau, Nizar J Bahlis
Smoldering multiple myeloma: taking the narrow over the wide path? Blood 143 (20) (2024)
Cyrille Touzeau, Amrita Y Krishnan, Philippe Moreau, Aurore Perrot, Saad Z Usmani, Salomon Manier, Michele Cavo, Carmen Martinez Chamorro, Ajay K Nooka, Thomas G Martin, Lionel Karlin, Xavier Leleu, Nizar J Bahlis, Britta Besemer, Lixia Pei, Sarah Stein, Shun Xin Wang Lin, Danielle Trancucci, Raluca I Verona, Suzette Girgis, Xin Miao, Clarissa Uhlar, Katherine Chastain, Alfred L Garfall
Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood (2024)
Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco daCosta DiBonaventura, Jinma Ren, Umberto Conte
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. British journal of haematology (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, Onsay Lau, Karl Calara-Nielsen, Cuc Davis, Jaymala Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S Wu, Philippe Moreau, Saad Z Usmani, Nizar J Bahlis, Niels W C J van de Donk, Raluca I Verona
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood 144 (6) (2024)
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, On Say Lau, Karl Nielsen, Cuc Davis, Jaymala H Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna D Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S Wu, Philippe Moreau, Saad Z Usmani, Nizar J Bahlis, Niels W C J van de Donk, Raluca I Verona
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in MajesTEC-1. Blood (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Holly Lee, Paola Neri, Nizar J Bahlis
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms. Blood 143 (13) (2024)
Paola Neri, Noemie Leblay, Holly Lee, Annamaria Gulla, Nizar J Bahlis, Kenneth C Anderson
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nature reviews. Clinical oncology (2024)
Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco daCosta DiBonaventura, Jinma Ren, Umberto Conte
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. British journal of haematology 204 (5) (2024)
Sikander Ailawadhi, Bertrand Arnulf, Krina K Patel, Michele Cavo, Ajay K Nooka, Salomon Manier, Natalie S Callander, Luciano José Megale Costa, Ravi Vij, Nizar J Bahlis, Philippe Moreau, Scott R Solomon, Ingerid Weum Abrahamsen, Rachid C Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesus G Berdeja, Sergio A Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender S Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa-Mckiver, Paula Rodriguez Otero
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood (2024)
Hervé Avet-Loiseau, Nizar J Bahlis
Smoldering Multiple Myeloma : Taking the narrow over the wide path? Blood (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Mohamad Mohty, Nizar J Bahlis, Ajay K Nooka, Marco daCosta DiBonaventura, Jinma Ren, Umberto Conte
Impact of elranatamab on quality of life: Patient-reported outcomes from MagnetisMM-3. British journal of haematology 204 (5) (2024)
Florent Malard, Paola Neri, Nizar J Bahlis, Evangelos Terpos, Nour Moukalled, Vania Tietsche de Moraes Hungria, Salomon Manier, Florent Malard
Multiple myeloma. Nature reviews. Disease primers 10 (1) (2024)
Holly Lee, Paola Neri, Nizar J Bahlis
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms. Blood (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Hervé Avet-Loiseau, Nizar J Bahlis
Smoldering Multiple Myeloma : Taking the narrow over the wide path? Blood (2024)
Herve Avet-Loiseau, Nizar J Bahlis
Smoldering multiple myeloma: taking the narrow over the wide path? Blood 143 (20) (2024)
Paola Neri, Holly Lee, Nizar J Bahlis
Artificial Intelligence Individualized Risk Classifier in Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Paola Neri, Noemie Leblay, Holly Lee, Annamaria Gulla, Nizar J Bahlis, Kenneth C Anderson
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nature reviews. Clinical oncology 21 (8) (2024)
Paola Neri, Holly Lee, Nizar J Bahlis
Artificial Intelligence Individualized Risk Classifier in Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Paola Neri, Holly Lee, Nizar J Bahlis
Artificial Intelligence Individualized Risk Classifier in Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (11) (2024)
Holly Lee, Paola Neri, Nizar J Bahlis
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: Efficacy, safety and resistance mechanisms. Blood (2024)
Diana Cortes-Selva, Tatiana Perova, Sheri Skerget, Deeksha Vishwamitra, Sarah Stein, Rengasamy Boominathan, Onsay Lau, Karl Calara-Nielsen, Cuc Davis, Jaymala Patel, Arnob Banerjee, Tara Stephenson, Clarissa Uhlar, Rachel Kobos, Jenna Goldberg, Lixia Pei, Danielle Trancucci, Suzette Girgis, Shun Xin Wang Lin, Liviawati S Wu, Philippe Moreau, Saad Z Usmani, Nizar J Bahlis, Niels W C J van de Donk, Raluca I Verona
Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood 144 (6) (2024)
Paula Rodriguez Otero, Niels W C J van de Donk, Kodandaram Pillarisetti, Ingrid Cornax, Deeksha Vishwamitra, Kathleen Gray, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Tara Masterson, Christoph Heuck, Colleen Kane, Raluca Verona, Phillipe Moreau, Nizar J Bahlis, Ajai Chari
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood cancer journal 14 (1) (2024)
Meletios- Athanasios Dimopoulos, Albert Ortiol, Hareth Nahi, Jesús San F Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung Soo Yoon, Dina Ben Yehuda, Paul Gerard Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Phillipe Moreau
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Meletios- Athanasios Dimopoulos, Albert Ortiol, Hareth Nahi, Jesús San F Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung Soo Yoon, Dina Ben Yehuda, Paul Gerard Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Phillipe Moreau
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Paul Gerard Richardson, Thierry Facon, Christopher P Venner, Nizar J Bahlis, Fritz Offner, Darrell White, Lionel Karlin, Lotfi Benboubker, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Miguel Villarreal, Philip Twumasi-Ankrah, Richard Labotka, Robert M Rifkin, Sagar Lonial, Shaji K Kumar, S Vincent Rajkumar, Philippe Moreau
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trial. EJHaem 4 (4) (2023)
Holly Lee, Sungwoo Ahn, Ranjan Maity, Noemie Leblay, Bachisio Ziccheddu, Marietta Truger, Monika Chojnacka, Anthony Cirrincione, Michael A Durante, Remi Tilmont, Elie Barakat, Mansour Poorebrahim, Sarthak Sinha, John McIntyre, Angela M Y Chan, Holly Wilson, Shari Kyman, Amrita Krishnan, Carl Ola Landgren, Wencke Walter, Manja Meggendorfer, Claudia Haferlach, Torsten Haferlach, Hermann Einsele, Klaus Martin Kortüm, Stefan Knop, Jean Baptiste Alberge, Andreas Rosenwald, Jonathan J Keats, Leo Rasche, Francesco Maura, Paola Neri, Nizar J Bahlis
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nature medicine (2023)
Alexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, Nizar J Bahlis, Henry Miles Prince, Ruben Niesvizky, Paula Rodrίguez-Otero, Joaquin Martinez Lopez, Guenther Koehne, Cyrille Touzeau, Yogesh Jethava, Hang Quach, Julien Depaus, Hisayuki Yokoyama, Afshin Eli Gabayan, Don A Stevens, Ajay K Nooka, Salomon Manier, Noopur Raje, Shinsuke Iida, Marc-Steffen Raab, Emma Searle, Eric Leip, Sharon T Sullivan, Umberto Conte, Mohamed Elmeliegy, Akos Czibere, Andrea Viqueira, Mohamad Mohty
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nature medicine (2023)
Noemie Leblay, Sungwoo Ahn, Rémi Tilmont, Mansour Poorebrahim, Ranjan Maity, Holly Lee, Elie Barakat, Jean-Baptiste Alberge, Sarthak Sinha, Arzina Jaffer, Benjamin G Barwick, Lawrence H Boise, Nizar J Bahlis, Paola Neri
Integrated Epigenetic and Transcriptional Single-Cell Analysis of t(11;14) Multiple Myeloma and Its BCL2 Dependency. Blood (2023)
Nizar J Bahlis, Caitlin L Costello, Noopur S Raje, Moshe Y Levy, Bhagirathbhai R Dholaria, Melhem Solh, Michael H Tomasson, Michael A Damore, Sibo Jiang, Cynthia Basu, Athanasia Skoura, Edward M Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P Chu, Andrew Dalovisio, Michael Sebag, Alexander M Lesokhin
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature medicine (2023)
Paola Neri, Benjamin G Barwick, David Jung, Jonathan C Patton, Ranjan Maity, Ines Tagoug, Caleb K Stein, Rémi Tilmont, Noemie Leblay, Sungwoo Ahn, Holly Lee, Seth J Welsh, Daniel L Riggs, Nicholas Stong, Erin Flynt, Anjan Thakurta, Jonathan J Keats, Sagar Lonial, Peter Leif Bergsagel, Lawrence H Boise, Nizar J Bahlis
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma. Blood cancer discovery (2023)
Meletios- Athanasios Dimopoulos, Albert Ortiol, Hareth Nahi, Jesús San F Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung Soo Yoon, Dina Ben Yehuda, Paul Gerard Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Phillipe Moreau
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Seth J Welsh, Benjamin G Barwick, Erin W Meermeier, Daniel L Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E Sharik, Megan T Du, Leslie D Abrego Rocha, Victoria M Garbitt, Caleb K Stein, Joachim L Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T Todd, Sochilt Brown, Zachary J Hammond, Nicklus H Cuc, Courtney Wittenberg, Camille Herzog, Anna V Roschke, Yulia N Demchenko, Wei-Dong D Chen, Peng Li, Wei Liao, Warren J Leonard, Sagar Lonial, Nizar J Bahlis, Paola Neri, Lawrence H Boise, Marta Chesi, Peter Leif Bergsagel
Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma. Blood cancer discovery (2023)
Meletios- Athanasios Dimopoulos, Albert Ortiol, Hareth Nahi, Jesús San F Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung Soo Yoon, Dina Ben Yehuda, Paul Gerard Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Phillipe Moreau
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 41 (8) (2023)
Meletios- Athanasios Dimopoulos, Albert Ortiol, Hareth Nahi, Jesús San F Miguel, Nizar J Bahlis, Saad Z Usmani, Neil Rabin, Robert Z Orlowski, Kenshi Suzuki, Torben Plesner, Sung Soo Yoon, Dina Ben Yehuda, Paul Gerard Richardson, Hartmut Goldschmidt, Donna Reece, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Phillipe Moreau
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Robert Puckrin, Holly Lee, Jason Tay, Peter Duggan, Sylvia McCulloch, Paola Neri, Nizar J Bahlis, Victor H Jimenez-Zepeda
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 29 (3) (2022)
Paul G Richardson, Maria-Victoria Mateos-Manteca, Annette J Vangsted, Karthik Ramasamy, Niels Abildgaard, P Joy Ho, Hang Quach, Nizar J Bahlis
The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease. Expert review of proteomics (2022)
Duncan K Brownsey, Ben C Rowley, Evgueni Gorobets, Koichiro Mihara, Ranjan Maity, James W Papatzimas, Benjamin S Gelfand, Morley D Hollenberg, Nizar J Bahlis, Darren J Derksen
Identification of ligand linkage vectors for the development of p300/CBP degraders. RSC medicinal chemistry 13 (6) (2022)
Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J Bahlis, Darrell White, Christine I Chen, Heather J Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P Venner, William I Bensinger, Noa Biran, Andrew DeCastro, Dane R Van Domelen, Chris Zhang, Jatin J Shah, Sharon Shacham, Michael G Kauffman, Ohad S Bentur, Brea Lipe
Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem 3 (4) (2022)
Herve Avet-Loiseau, Jesús San F Miguel, Tineke Casneuf, Shinsuke Iida, Sagar Lonial, Saad Z Usmani, Andrew Spencer, Philippe Moreau, Torben Plesner, Katja Weisel, Jon Ukropec, Christopher Chiu, Sonali Trivedi, Himal Amin, Maria Krevvata, Priya Ramaswami, Xiang Qin, Mia Qi, Steven Sun, Ming Qi, Rachel Kobos, Nizar J Bahlis
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (10) (2021)
Paul Gerard Richardson, Shaji K Kumar, Tamás Masszi, Norbert Grzasko, Nizar J Bahlis, Markus Hansson, Luděk Pour, Irwindeep Sandhu, Peter Ganly, Bartrum W Baker, Sharon R Jackson, Anne-Marie Stoppa, Peter Gimsing, Laurent Garderet, Cyrille Touzeau, Francis K Buadi, Jacob P Laubach, Michele Cavo, Mohamed Darif, Richard Labotka, Deborah Berg, Philippe Moreau
Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (22) (2021)
Nizar J Bahlis, Rachid Baz, Simon J Harrison, Hang Quach, Shir Jing Ho, Annette Juul Vangsted, Torben Plesner, Phillipe Moreau, Simon D Gibbs, Sheryl Coppola, Xiaoqing Yang, Abdullah Al Masud, Jeremy A Ross, Orlando Bueno, Jonathan L Kaufman
Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (32) (2021)